Table 1.
Patient Characteristics by OAC Use
| Characteristic | OAC Use (n=837) | No OAC Use (n=8729) | P Value |
|---|---|---|---|
| Age, y, mean±SD | 71.7±11.2 | 65.5±12.1 | <0.01 |
| Male | 621 (74.2) | 6308 (72.3) | 0.23 |
| White | 778 (93.0) | 7908 (90.6) | 0.024 |
| BMI, kg/m2, mean±SD | 29.7±15.4 | 29.2±7.3 | 0.16 |
| Current/recent smoking (within 1 year) | 75 (8.96) | 1608 (18.4) | <0.01 |
| Hypertension | 750 (89.6) | 7111 (81.5) | <0.01 |
| Dyslipidemia | 793 (94.7) | 8110 (92.9) | 0.045 |
| Family history of CAD | 132 (15.8) | 2082 (23.9) | <0.01 |
| Renal failure (currently on dialysis or creatinine >2 mg/dL) | 76 (9.08) | 453 (5.19) | <0.01 |
| Cerebrovascular disease | 245 (29.3) | 1177 (13.5) | <0.01 |
| Peripheral artery disease | 195 (23.3) | 1380 (15.8) | <0.01 |
| Chronic lung disease | 172 (20.6) | 1152 (13.2) | <0.01 |
| Diabetes mellitus | 342 (40.9) | 2977 (34.1) | <0.01 |
| Prior heart failure | 344 (41.1) | 1191 (13.6) | <0.01 |
| Prior myocardial infarction | 407 (48.6) | 3023 (34.6) | <0.01 |
| Prior valve surgery | 115 (13.7) | 160 (1.83) | <0.01 |
| Prior PCI | 333 (39.8) | 3329 (38.1) | 0.35 |
| Prior CABG | 278 (33.2) | 1598 (18.3) | <0.01 |
| Indication for oral anticoagulant | |||
| Atrial fibrillation/flutter | 653 (78.0) | — | — |
| Venous thromboembolism | 137 (16.4) | — | — |
| Left ventricular dysfunction, aneurysm, or thrombus | 76 (9.08) | — | — |
| Hypercoagulable syndrome | 49 (5.85) | — | — |
| Valvular heart disease | 39 (4.66) | — | — |
| Cardioembolic stroke | 14 (1.67) | — | — |
| Other | 37 (4.42) | — | — |
| Type of OAC | |||
| Warfarin | 771 (92.2) | — | — |
| Dabigatran | 39 (4.67) | — | — |
| Rivaroxaban | 20 (2.39) | — | — |
| Apixaban | 3 (0.36) | — | — |
| Other | 4 (0.48) | — | — |
| P2Y12 inhibitor at admission | 178 (21.3) | — | — |
| Type of P2Y12 inhibitor | |||
| Clopidogrel | 173 (97.2) | — | — |
| Ticagrelor | 1 (0.56) | — | — |
| Prasugrel | 3 (1.69) | — | — |
| Other | 1 (0.56) | — | — |
| Aspirin at admission | 592 (70.7) | — | — |
| Bridging therapy among elective PCIs | 68/307 (22.1) | — | — |
| OAC among survivors to discharge | 727/816 (89.1) | — | — |
| P2Y12 inhibitor among survivors to discharge | 790/816 (96.8) | 8237/8541 (96.4) | 0.58 |
| Type of P2Y12 inhibitor | |||
| Clopidogrel | 773/790 (97.8) | 7489/8541 (87.7) | <0.01 |
| Ticagrelor | 10/790 (1.27) | 466/8541 (5.46) | |
| Prasugrel | 7/790 (0.89) | 322/8541 (3.77) | |
| Aspirin among survivors at discharge | 800/816 (98.0) | 8340/8541 (97.6) | 0.48 |
| Triple therapy among survivors at discharge | 693/816 (84.9) | — | — |
Data are shown as n (%) except as noted. BMI indicates body mass index; CABG, coronary artery bypass grafting; CAD, coronary artery disease; OAC, oral anticoagulant; PCI, percutaneous coronary intervention.